Full history for every metric is available with a Kvantra account

Stock profile
DaVita Inc. logo

DaVita Inc. (DVA)

Country: United States of AmericaSector: HealthcareIndustry: Medical - Care FacilitiesExchange: NYSE
P/E TTM
12.6
History
P/E NTM
9.8
Market cap
10.13B
Currency USD
KvantraRankAbout78
IValue82
IIQuality72
IIIMomentum79
Current price
161.03 USD+3.00%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$bn11.611.611.612.112.813.614.214.2
Operating profit$bn2.012.10
Net profit$bn0.770.980.560.690.940.750.921.13
EPS reported$9.8412.74
Operating cashflow per share$25.4229.30
Capex per share$7.769.04
FCF per share$17.6620.27
Free cash flow$bn1.311.29
Net debt$bn14.312.8
Book value equity$bn-0.65-0.59
Book value per share$-8.58-9.02
Number of sharesm75.8965.5
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx11.5512.64
P/B LTMx-12.95-17.14
P/S LTMx0.620.71
P/FCF LTMx6.437.83
EV/EBITDA LTMx8.608.81
EV/Sales LTMx1.671.74
Earnings Yield LTM%8.66%7.91%
FCF Yield%15.54%12.77%
Quality
ROE%-114.70%-133.21%
ROIC%10.58%10.69%
Operating margin%14.74%14.84%
Gross margin%27.00%30.96%
FCF/Sales%9.61%9.13%
Growth and momentum
EPS Growth YoY%-8.29%+31.20%
Sales Growth YoY%+6.46%+6.38%
Net Income Growth YoY%-20.24%+19.19%
FCF Growth%-10.63%+0.11%
Operating Profit Growth%-3.82%+2.70%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%16.31%
FCF/Debtx0.090.10
Net Debt/EBITDAx5.414.61
EBIT/Net interestx3.663.76
Net debt/market cap%169.19%126.63%
Net debt/Equityx-21.91-21.70
Gross debt/equityx-23.12-22.66

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price161.03 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Websitedavita.com
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

DaVita Inc. (DVA)

DVA · NYSE · Healthcare
161.03 USD+3.00%
Sign up to track this stock
Benchmarks
KvantraRank78
Market cap10.13B
P/E NTM9.8
P/E TTM12.6
KvantraRank?78 / 100
Value
82
Quality
72
Momentum
79
Financialsin USD
20242025TTM2026E
Analyst target
Consensus
Current161.03 USD
Upside
Price consensus
Last year average price target
Current price161.03 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Websitedavita.com
IndustryMedical - Care Facilities
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free